Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nuvation Bio, Inc.

7.15
+2.3548.96%
Post-market: 7.200.0500+0.70%19:59 EST
Volume:59.11M
Turnover:401.22M
Market Cap:2.45B
PE:-11.17
High:7.35
Open:4.99
Low:4.94
Close:4.80
52wk High:7.35
52wk Low:1.54
Shares:342.83M
Float Shares:231.05M
Volume Ratio:8.07
T/O Rate:25.58%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6400
EPS(LYR):-2.1131
ROE:-52.49%
ROA:-24.82%
PB:7.52
PE(LYR):-3.38

Loading ...

Nuvation Bio Initiated at Buy by Jefferies

Dow Jones
·
Sep 30

U.S. RESEARCH ROUNDUP-Electronic Arts, Kala Bio, Semtech

Reuters
·
Sep 30

Nuvation Bio Inc : Jefferies Initiates Coverage With Buy Rating; Target Price $10

THOMSON REUTERS
·
Sep 30

Nuvation Bio Inc. Unveils Presentation Highlighting Breakthrough Oncology Advancements and Strategic Developments

Reuters
·
Sep 23

Sector Update: Health Care Stocks Rise Pre-Bell Friday

MT Newswires Live
·
Sep 19

Nuvation Bio's Ibtrozi Gets Japan Approval for Advanced ROS1-positive Non-Small Cell Lung Cancer

MT Newswires Live
·
Sep 19

Nuvation Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 19

Nuvation Bio announces Japan MHLW approval for Ibtrozi

TIPRANKS
·
Sep 19

Nuvation Bio Inc: Ibtrozi Will Be Marketed in Japan by Nippon Kayaku

THOMSON REUTERS
·
Sep 19

Nuvation Bio: Upon First Establishment of Reimbursement Price in Japan, Co to Receive a USD $25 Mln Milestone Payment

THOMSON REUTERS
·
Sep 19

Nuvation Bio Receives Approval From Japan’s Ministry of Health, Labour and Welfare for Ibtrozitm for Patients With Advanced Ros1-Positive Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 19

Nuvation Bio Price Target Maintained With a $6.00/Share by Wedbush

Dow Jones
·
Sep 08

Nuvation Bio Says Potential Non-Small Cell Lung Cancer Drug Shows 'Impressive' Progression-Free Survival

MT Newswires Live
·
Sep 08

Nuvation Bio Announces Promising Results from Phase 2 Studies of IBTROZI™ in ROS1-Positive Lung Cancer at 2025 Conference

Reuters
·
Sep 07

Nuvation Bio Announces New Data From Pivotal Clinical Studies of Ibtrozi™ (Taletrectinib) in Advanced Ros1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

THOMSON REUTERS
·
Sep 07

Nuvation Bio Up Over 5%, On Track for Highest Close Since August 2024 -- Data Talk

Dow Jones
·
Sep 05

Nuvation Bio Inc. to Attend Cantor Global Healthcare Conference 2025 in New York

Reuters
·
Aug 28

Nuvation Bio Is Maintained at Outperform by RBC Capital

Dow Jones
·
Aug 09

Stock Track | Nuvation Bio (NUVB) Soars 5.13% on Positive Analyst Ratings and Price Target Hikes

Stock Track
·
Aug 08

RBC Raises Price Target on Nuvation Bio to $7 From $6, Keeps Outperform, Speculative Risk

MT Newswires Live
·
Aug 08